ORGO Organogenesis Holdings Inc.

CIK 0001661181 41 ready 8-Ks latest August 6, 2026, 4:45 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 41

Latest filing August 6, 2026, 4:45 PM ET

Top materiality 0.90

Event mix earnings ×21 · other_material ×11 · other ×4

Sentiment 11 pos · 12 neg · 18 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ORGO

Highest-materiality recent filing

Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed

August 6, 2026, 4:11 PM ET earnings materiality 0.90 negative item 2.02 item 9.01

Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.
Net loss $96.3M ($0.77/share) vs $9.4M loss ($0.10/share) in Q2 2025.

Read filing →

August 6, 2026, 4:45 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Organogenesis enters $75M at-the-market equity distribution agreement with BTIG and Citizens JMP

Up to $75M of Class A common stock may be sold from time to time through BTIG and Citizens JMP Securities.
August 6, 2026, 4:11 PM ET earnings materiality 0.90 negative item 2.02 item 9.01

Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed

Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.
June 16, 2026, 4:32 PM ET other materiality 0.30 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×3

Organogenesis shareholders elect 9 directors, approve say-on-pay and auditor at annual meeting

All 9 director nominees elected; Glenn H. Nussdorf received lowest support (61M for, 24.3M withheld).
May 7, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered

Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.
February 26, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline

Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).
February 23, 2026, 6:59 PM ET leadership materiality 0.30 neutral item 5.02

Organogenesis appoints Patrick McGuire as CAO; Francisco remains CFO

Patrick McGuire, 40, appointed Chief Accounting Officer and principal accounting officer effective Feb 18, 2026; was VP Corporate Controller since Sep 2023.
December 29, 2025, 6:59 PM ET other material materiality 0.35 neutral item 1.01 item 9.01 ◈ Material Agreements

Organogenesis extends Canton lease terms through 2032 with related-party landlords; rent escalates 3% annually

Extended leases at 65 Dan Road and 150 Dan Road from Dec 31, 2027 to Dec 31, 2032, with an option to extend to Dec 31, 2034.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance

Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).
September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 7.01 item 8.01 item 9.01

Organogenesis second Phase 3 ReNu knee OA trial misses primary endpoint; pre-BLA meeting planned

Second Phase 3 (n=594) did not meet primary endpoint: WOMAC pain reduction difference -0.5 favoring ReNu (p=0.0393 vs target p=0.023).
August 7, 2025, 7:59 PM ET earnings materiality 0.85 negative item 1.01 item 2.02 item 9.01

Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test

Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.
June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07

Organogenesis stockholders approve Series A conversion issuance and director elections at 2025 annual meeting

Stockholders approved issuance of >20% of Class A common stock upon conversion of Series A Preferred at less than Nasdaq minimum price.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed

Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.
March 27, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Organogenesis posts investor presentation with no disclosed material changes; details unavailable

Company posted investor presentation to its website on March 27, 2025.
February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M

Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).
December 2, 2024, 6:59 PM ET other material materiality 0.35 neutral item 1.01 item 9.01

Organogenesis repurchases 500K shares from director trust at $4.057/sh for $2M total

Repurchase of 500,000 shares from GN 2016 Family Trust (related to director Glenn Nussdorf) at $4.057/share, total $2.03M.
November 22, 2024, 6:59 PM ET other material materiality 0.55 positive item 1.01 item 8.01 item 9.01

Organogenesis signs 16.5-year lease for 122,000 sq ft RI biomanufacturing facility, base rent $43/sq ft from 2026

Leased 122,000 sq ft at 100 Technology Way, Smithfield, RI for biomanufacturing expansion.
November 13, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 5.03 item 2.04 item 3.02 item 3.03 item 5.02 item 8.01 item 9.01 ◈ executive_change

Organogenesis raises $130M convertible preferred, repurchases 7.4M shares, appoints Avista director

Sold 130,000 shares of Series A Convertible Preferred Stock at $1,000/share for gross proceeds of $130M.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance

Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).
August 8, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs

Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).
June 21, 2024, 7:59 PM ET other materiality 0.30 neutral item 5.02 item 5.07 item 9.01

Stockholders approve 15.9M share increase to 2018 Equity Incentive Plan

All 11 director nominees elected; votes ranged from 41.5M to 68.4M for, with broker non-votes of 39.3M.
May 9, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M

Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.
April 3, 2024, 7:59 PM ET litigation materiality 0.55 positive item 8.01 item 9.01

Court dismisses securities fraud lawsuit against Organogenesis, CEO and CFO with prejudice

U.S. District Court for Eastern District of New York granted motion to dismiss on March 29, 2024.
February 29, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M

Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).
November 9, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q3 revenue down 7% to $108.5M; net income rises to $3.2M; guides FY rev down 1-4%

Net revenue $108.5M, down $8.3M YoY; Advanced Wound Care fell 7% to $101.4M; Surgical & Sports Med fell 2% to $7.2M.
August 9, 2023, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Organogenesis Q2 revenue $117.3M (-3% YoY); withdraws FY2023 guidance on Medicare LCDs

Net revenue of $117.3M, down 3% YoY from $121.4M; net income $5.3M vs $8.7M.
June 16, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Organogenesis shareholders elect 11 directors, approve say-on-pay, ratify RSM as auditor

All 11 director nominees elected; Glenn Nussdorf had 23.3M withhold (35.6%) and Arthur Leibowitz 20.3M withhold (31.0%).
May 10, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q1 rev $107.6M (+11% YoY); raises FY2023 revenue to $454-466M

Net revenue $107.6M, up 11% YoY; net loss $3.0M vs $0.9M loss year-ago.
March 1, 2023, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Organogenesis Q4 revenue down 10% YoY; FY2023 guidance flat to +2%

Q4 2022 net revenue $115.5M (-10% YoY); net income $7.5M vs $51.0M in Q4 2021.
November 9, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q3 net income plummets to $0.2M on $116.9M revenue; cuts FY2022 guidance

Net revenue $116.9M (+3% YoY), but net income $0.2M vs $12.6M in Q3 2021.
August 9, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Organogenesis Q2 revenue $121.4M (-1% YoY); net income falls 58% to $8.7M

Net revenue $121.4M vs $123.2M in Q2 2021; adjusted revenue up 3% excluding ReNu/NuCel.
June 27, 2022, 7:59 PM ET other material materiality 0.35 neutral item 3.03 item 5.03 item 5.02 item 5.07 item 9.01

Organogenesis stockholders approve director removal amendment and equity plan increase

Certificate of Incorporation amended to allow director removal without cause by majority vote.
May 10, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Organogenesis Q1 revenue down 4% to $98.1M; net income drops to $0.1M from $9.9M

Net revenue $98.1M, down 4% YoY; adjusted net income $1.2M vs $11.2M.
May 5, 2022, 7:59 PM ET leadership materiality 0.50 positive item 5.02 item 9.01 ◈ executive_change ×2

Organogenesis appoints Michele Korfin and Gilberto Quintero to board as independent directors

Michele Korfin appointed as independent director; brings experience from Gamida Cell, Kite Pharma, Celgene.
April 15, 2022, 7:59 PM ET other material materiality 0.40 neutral item 5.08 item 8.01

Organogenesis sets 2022 annual meeting for June 23; expands board to 11 members

2022 Annual Meeting scheduled for June 23, 2022; record date April 25, 2022.
March 1, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Organogenesis Q4 revenue $128.6M (+20% YoY), FY22 guidance $485M-$515M

Q4 net revenue $128.6M (up 20% YoY); Advanced Wound Care $121.4M (+30%), Surgical & Sports Medicine $7.2M (-45%).
February 18, 2022, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

Organogenesis appoints Michael J. Driscoll to board as independent director

Dr. Driscoll appointed independent director effective Feb 15, 2022, expanding board to nine members.
December 30, 2021, 6:59 PM ET other materiality 0.15 neutral item 5.07

Organogenesis shareholders elect 8 directors and ratify RSM US LLP as auditor

All 8 director nominees elected: Alan A. Ades, Robert Ades, Duraibabu, Erani, Giacomin, Gillheeney, Leibowitz, Nussdorf.
November 22, 2021, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 item 9.01 ◈ executive_change

Organogenesis appoints Prathyusha Duraibabu to board, regains Nasdaq audit committee compliance

Prathyusha Duraibabu appointed independent director effective Nov 19, 2021; also joins audit committee.
November 9, 2021, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Organogenesis Q3 revenue $113.8M (+13% YoY), net income $12.6M, FY2021 guidance $458-470M

Net revenue $113.8M (+13% YoY); Advanced Wound Care $107.3M (+19%), Surgical & Sports Medicine $6.4M (-41%).
August 16, 2021, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 1.02 item 9.01

Organogenesis buys Canton facility for $6M from directors/stockholders; terminates lease

Purchased land and building at 275 Dan Road, Canton, MA for $6M cash from seller owned by directors/stockholders.
August 9, 2021, 7:59 PM ET earnings materiality 0.85 positive item 1.01 item 1.02 item 2.02 item 2.03 item 7.01 item 9.01

Organogenesis Q2 revenue $123.2M (+79%), net income $20.7M; new $200M credit facility

Net revenue $123.2M (+79% YoY); Advanced Wound Care $111.4M (+87%), Surgical & Sports Med $11.8M (+27%).